Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer

被引:184
作者
Schardt, JA
Meyer, M
Hartmann, CH
Schubert, F
Schmidt-Kittler, O
Fuhrmann, C
Polzer, B
Petronio, M
Eils, R
Klein, CA
机构
[1] Univ Munich, Inst Immunol, D-80336 Munich, Germany
[2] Deutsch Krebsforschungszentrum, Div Theoret Bioinformat, D-69120 Heidelberg, Germany
[3] Univ Heidelberg, Inst Pharm & Mol Biotechnol, Dept Bioinformat & Funct Genom, D-69120 Heidelberg, Germany
关键词
D O I
10.1016/j.ccr.2005.08.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chromosomal instability in human breast cancer is known to take place before mammary neoplasias display morphological signs of invasion. We describe here the unexpected finding of a tumor cell population with normal karyotypes isolated from bone marrow of breast cancer patients. By analyzing the same single cells for chromosomal aberrations, subchromosomal allelic losses, and gene amplifications, we confirmed their malignant origin and delineated the sequence of genomic events during breast cancer progression. On this trajectory of genomic progression, we identified a subpopulation of patients with very early HER2 amplification. Because early changes have the highest probability of being shared by genetically unstable tumor cells, the genetic characterization of disseminated tumor cells provides a novel rationale for selecting patients for targeted therapies.
引用
收藏
页码:227 / 239
页数:13
相关论文
共 44 条
  • [1] Histological and biological evolution of human premalignant breast disease
    Allred, DC
    Mohsin, SK
    Fuqua, SAW
    [J]. ENDOCRINE-RELATED CANCER, 2001, 8 (01) : 47 - 61
  • [2] Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice
    Artandi, SE
    Chang, S
    Lee, SL
    Alson, S
    Gottlieb, GJ
    Chin, L
    DePinho, RA
    [J]. NATURE, 2000, 406 (6796) : 641 - 645
  • [3] Tyrosine kinase inhibitors: Why does the current process of clinical development not apply to them?
    Arteaga, CL
    Baselga, J
    [J]. CANCER CELL, 2004, 5 (06) : 525 - 531
  • [4] Aubele M, 2000, INT J CANCER, V85, P82, DOI 10.1002/(SICI)1097-0215(20000101)85:1<82::AID-IJC15>3.0.CO
  • [5] 2-S
  • [6] DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
    Bartkova, J
    Horejsi, Z
    Koed, K
    Krämer, A
    Tort, F
    Zieger, K
    Guldberg, P
    Sehested, M
    Nesland, JM
    Lukas, C
    Orntoft, T
    Lukas, J
    Bartek, J
    [J]. NATURE, 2005, 434 (7035) : 864 - 870
  • [7] Borgen E, 1998, J PATHOL, V185, P427, DOI 10.1002/(SICI)1096-9896(199808)185:4<427::AID-PATH127>3.0.CO
  • [8] 2-7
  • [9] Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer.
    Braun, S
    Pantel, K
    Muller, P
    Janni, W
    Hepp, F
    Kentenich, CRM
    Gastroph, S
    Wischnik, A
    Dimpfl, T
    Kindermann, G
    Riethmuller, G
    Schlimok, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (08) : 525 - 533
  • [10] Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients
    Braun, S
    Kentenich, C
    Janni, W
    Hepp, F
    de Waal, J
    Willgeroth, F
    Sommer, H
    Pantel, K
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) : 80 - 86